Three Hidden Small-Caps Flying Under the Radar While Everyone Stares at the SpaceX Hype Machine

Look, we get it. SpaceX closed up 19% on a $75 billion IPO and Elon Musk is now technically the world's first trillionaire. Very cool. Very loud. Zero edge for you. While the financial internet collectively lost its mind, we went digging in the quieter corners of the market — and found three names worth knowing.

First up: $NUVL (Nuvalent). Tiny oncology biotech, sub-$5B market cap, developing next-gen ROS1 and ALK inhibitors for cancer patients who've already failed first-line treatment. The catalyst? Readout data expected later this year that could leapfrog current standard-of-care. Analysts who cover it are bullish; most analysts don't cover it at all. Second: $ASCS isn't publicly traded, but the Bloomberg quiz flagged Asics spinning off its Onitsuka Tiger brand — a play hiding inside a Japanese parent. The pure domestically listed angle here points to $SKX (Skechers) as the under-$10B footwear compounder most likely to vacuum up market share from any spin-off distraction. Third: $CURO — consumer finance, ugly sector, exactly the kind of name nobody wants to say at a dinner party, which is historically where the returns are.

The SpaceX circus will eventually quiet down. Discovery doesn't happen in the spotlight — it happens when everyone else is busy looking somewhere else.